Titan Pharma’s Probuphine implant to treat OUD gains media attention in Canada

Television station, CFJC, of Kamloops, British Columbia, Canada has produced a segment about the first patient in the region to receive Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphineas a new treatment in the battle against heroin and prescription painkiller addiction.

“This is going to be a game-changer in treating opioid use disorder,” Dr. Mandy Manak, who implanted one of her patients with Probuphine, told the TV station. “It’s also going to be a game-changer in how people live their lives in recovery.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.